专利号:US-9751877-B2 优先权日:2012-09-21 标题 :Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders 发明人:PETTERSSON MARTIN YOUNGJIN; JOHNSON DOUGLAS SCOTT; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; AM ENDE CHRISTOPHER WILLIAM; GREEN MICHAEL ERIC; PATEL NANDINI CHATURBHAI; STIFF CORY MICHAEL; TRAN TUAN PHONG; KAUFFMAN GREGORY WAYNE; STEPAN ANTONIA FRIEDERIKE; VERHOEST PATRICK ROBERT 权利人:PFIZER 摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
专利号:IT-201700008702-A1 优先权日:2017-01-26 标题:METHOD OF SYNTHESIS OF SELEGILINA BASE
专利号:ES-2794012-T3 优先权日:2008-10-27 标题 :Intermediaries for the synthesis of mTOR kinase inhibitors
专利号:US-2006205787-A1 优先权日:2005-01-25 标题 :Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione 发明人:MULLER GEORGE W; CHEN ROGER S 权利人:MULLER GEORGE W; CHEN ROGER S 摘要:This invention relates to racemic and stereomerically pure 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione, and prodrugs, salts and solvates thereof. Synthesis, methods of use, and pharmaceutical compositions of racemic and stereomerically pure 4-amino-2-(3-methyl-2,6-dioxo-piperidine-3-yl)-isoindole-1,3-dione, and prodrugs, salts and solvates thereof, are disclosed.
专利号:US-9771379-B2 优先权日:2015-09-24 标题:N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides 发明人:BRODNEY MICHAEL AARON; BUTLER CHRISTOPHER RYAN; ZHANG LEI; O'NEILL BRIAN THOMAS 权利人:PFIZER 摘要:The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, n nwherein the variables R 1 , R 2 , R 3 , R 4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
专利号:WO-2012172449-A1 优先权日:2011-06-13 标题:Lactams as beta secretase inhibitors 发明人:BRODNEY MICHAEL AARON 权利人:PFIZER; BRODNEY MICHAEL AARON 摘要:Compound and pharmaceutically acceptable salts of the compound are disclosed, wherein the compound has the structure (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. The compound of formula I is useful as beta secretase inhibitor for use in the treatment of Alzheimer's and other neurodegenerative and/or neurological disorders.
1: Lees AJ. Selegiline hydrochloride and cognition. Acta Neurol Scand Suppl. 1991;136:91-4. doi: 10.1111/j.1600-0404.1991.tb05027.x. 12(2):159-174. doi: 10.4155/tde-2020-0118. Epub 2021 Feb 9. Suppl(Suppl):29-37. doi: 10.1136/jnnp.52.suppl.29. 5: George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry. 2003 Jan 15;53(2):136-43. doi: 10.1016/s0006-3223(02)01454-3. 17(3):199-206. doi: 10.2133/dmpk.17.199. 46(11):1037-40. 19(1):46-56. doi: 10.2174/1871524919666181126124846. 25(8):1597-613. doi: 10.1016/s0278-5846(01)00205-6. 44(3):865-77. doi: 10.3109/21691401.2014.998824. Epub 2015 Jun 4. 44(10):1613-1621. doi: 10.1080/03639045.2018.1483387. Epub 2018 Aug 20. 26(2):150-161. doi: 10.1080/1061186X.2017.1350858. Epub 2017 Jul 18. 13(10):1535-40. doi: 10.1023/a:1016035730754. 16(4):417-425. doi: 10.2174/1570163815666180418144019. 40(5):632-8. doi: 10.3109/03639045.2014.884124. Epub 2014 Feb 12. 57(1):37-42. doi: 10.1007/s002280100278. 8:542. doi: 10.3389/fneur.2017.00542.
合成参考文献
摘要:Mahmood I; Clin Pharmacokinet 33 (2): 91-102 (1997) 参考文献:10.1007/s00228-002-0469-y 摘要:Palovaara S, Anttila M, Nyman L, Laine K. Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline. European Journal of Clinical Pharmacology. 2002 May 22;58(4):259–63. doi: 10.1007/s00228-002-0469-y.